XOMA Royalty (XOMA) Current Deferred Revenue (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Current Deferred Revenue came in at $1.3 million in Q1 2026, down 5.77% year-on-year from $1.4 million in Q1 2025, and up 1.81% quarter-over-quarter from $1.3 million in Q4 2025.
XOMA Royalty (XOMA) Current Deferred Revenue (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Current Deferred Revenue across 17 years of filings, most recently posting $1.3 million for Q1 2026.
- Current Deferred Revenue for Q1 2026 came in at $1.3 million, down 5.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (down 5.77% YoY), and the FY2025 annual result was $1.3 million, down 6.83% from the prior year.
- Current Deferred Revenue came in at $1.3 million for Q1 2026 at XOMA Royalty, up from $1.3 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $2.3 million in Q2 2024 to a low of $1.3 million in Q4 2025.
- The 5-year median for Current Deferred Revenue is $1.7 million (2022), against an average of $1.7 million.
- Across the five-year window, Current Deferred Revenue rose 21.95% in 2023 and sank 37.65% in 2025, its largest moves.
- XOMA Royalty's Current Deferred Revenue stood at $1.9 million in 2022, then increased by 11.27% to $2.1 million in 2023, then tumbled by 35.59% to $1.4 million in 2024, then declined by 6.83% to $1.3 million in 2025, then grew by 1.81% to $1.3 million in 2026.
- The last three Current Deferred Revenue figures came in at $1.3 million (Q1 2026), $1.3 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.29 Mn |
| Dec 31, 2025 | 1.27 Mn |
| Sep 30, 2025 | 1.32 Mn |
| Jun 30, 2025 | 1.43 Mn |
| Mar 31, 2025 | 1.37 Mn |
| Dec 31, 2024 | 1.36 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 2.30 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Dec 31, 2023 | 2.11 Mn |
| Sep 30, 2023 | 2.08 Mn |
| Jun 30, 2023 | 2.03 Mn |
| Mar 31, 2023 | 1.97 Mn |
| Dec 31, 2022 | 1.90 Mn |
| Sep 30, 2022 | 1.70 Mn |
| Jun 30, 2022 | 1.67 Mn |
| Mar 31, 2022 | 1.62 Mn |
| Dec 31, 2021 | 1.64 Mn |
| Sep 30, 2021 | 1.54 Mn |
| Jun 30, 2021 | 1.50 Mn |